Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros












Intervalo de ano de publicação
1.
West Afr J Med ; 40(11 Suppl 1): S25, 2023 Nov 10.
Artigo em Inglês | MEDLINE | ID: mdl-37978874

RESUMO

Introduction: Gastrointestinal stromal tumours (GISTs) are neoplastic lesions that primarily affect the digestive tract and develop from interstitial cells of Cajal. Due to their malignant potential and personalized treatment, these lesions require histopathologic and immunohistochemical characterization. In this investigation, the sex, age, lesional sites of origin, histopathologic types, the prevalence of HER-2 expression, prognostic indices (based on tumour size and mitotic figures), expression of CD117 and DOG1, and characteristics of patients with GIST were all characterized. Methodology: This is a retrospective cross-sectional analysis of GIST cases seen at four tertiary healthcare centers in Nigeria over ten years (2008 to 2017) and investigated utilizing histopathological and immunohistochemical (CD117, DOG1, and HER-2) methods. Result: In this study, there were twenty GIST cases. Notably, the majority (40%) of the cases had tumours with sizes between 7.0 and 8.0, the stomach was the most frequent site (70%) and the spindle cell type of GIST was the most prevalent (80%) histopathological type. Additionally, the stomach was significantly associated with GIST as an origin site (with a P value of 0.001), and 100% and 50% of these tumours were immunoreactive with CD117 and DOG1 respectively. Finally, HER-2 immunoreactivity was negatively stained with GIST tumour. Conclusion: In our study, GISTs most frequently develop in the stomach, and CD117& DOG1 are essential for correctly diagnosing these tumours. However, HER-2 immunoreactivity is a predictive marker of survival for personalized care.


Assuntos
Tumores do Estroma Gastrointestinal , Humanos , Tumores do Estroma Gastrointestinal/diagnóstico , Tumores do Estroma Gastrointestinal/metabolismo , Tumores do Estroma Gastrointestinal/patologia , Biomarcadores Tumorais/análise , Biomarcadores Tumorais/metabolismo , Proteínas de Neoplasias/análise , Proteínas de Neoplasias/metabolismo , Estudos Retrospectivos , Nigéria/epidemiologia , Estudos Transversais
2.
Ann Afr Med ; 22(4): 501-507, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38358152

RESUMO

Aims: Gastrointestinal stromal tumors (GISTs) are neoplastic lesions that primarily affect the digestive tract and develop from interstitial cells of Cajal. These lesions require histopathological and immunohistochemical characterization due to their malignant potential and personalized treatment. In this investigation, the sex, age, lesional sites of origin, histopathological types, the prevalence of human epidermal growth factor receptors (HER-2) expression, prognostic indices (based on tumor size and mitotic figures), expression of CD117 and DOG1, and characteristics of patients with GIST were all characterized. Materials and Methods: This was a retrospective cross-sectional analysis of GIST cases seen at four tertiary health-care centers in Nigeria over a 10-year period (2008-2017) and investigated utilizing histopathological and immunohistochemical (CD117, DOG1, and HER-2) methods. Results: In this investigation, there were twenty GIST cases. Notably, the majority (40%) of the cases had tumors with sizes between 7.0 and 8.0 cm; the stomach was the most frequent site (70%) and the spindle cell type of GIST was the most prevalent (80%) histopathological type. In addition, the stomach was significantly associated with GIST as an origin site (with a P = 0.001), and 100% and 50% of these tumors were immunoreactive with CD117 and DOG1, respectively. Conclusions: In our study, GISTs most frequently develop in the stomach, and CD117 and DOG1 are essential for correctly diagnosing these tumors. However, HER-2 immunoreactivity is a predictive marker of survival for personalized care.


Résumé Objectifs: Les tumeurs stromales gastro-intestinales (GIST) sont des lésions néoplasiques qui affectent principalement le tube digestif et se développent à partir des cellules interstitielles de Cajal. Ces lésions nécessitent une caractérisation histopathologique et immunohistochimique en raison de leur potentiel malin et d'un traitement personnalisé. Dans cette enquête, le sexe, l'âge, les sites d'origine des lésions, les types histopathologiques, la prévalence de l'expression des récepteurs du facteur de croissance épidermique humain (HER-2), les indices pronostiques (basés sur la taille de la tumeur et les chiffres mitotiques), l'expression de CD117 et DOG1, et les caractéristiques des patients atteints de GIST ont toutes été caractérisées. Matériels et méthodes: Il s'agissait d'une analyse transversale rétrospective de cas de GIST observés dans quatre centres de soins de santé tertiaires au Nigeria sur une période de 10 ans (2008-2017) et étudiée à l'aide d'analyses histopathologiques et immunohistochimiques (CD117, DOG1 et HER). 2) méthodes. Résultats: Dans cette enquête, il y a eu vingt cas de GIST. Notamment, la majorité (40 %) des cas présentaient des tumeurs mesurant entre 7,0 et 8,0 cm ; l'estomac était le site le plus fréquent (70 %) et le type de GIST à cellules fusiformes était le type histopathologique le plus répandu (80 %). De plus, l'estomac était significativement associé au GIST comme site d'origine (avec un P = 0,001) et 100 % et 50 % de ces tumeurs étaient immunoréactives avec CD117 et DOG1, respectivement. Conclusions: Dans notre étude, les GIST se développent le plus souvent dans l'estomac, et CD117 et DOG1 sont essentiels pour diagnostiquer correctement ces tumeurs. Cependant, l'immunoréactivité HER-2 est un marqueur prédictif de survie pour une prise en charge personnalisée. Mots-clés: Biomarqueurs, tumeurs stromales gastro-intestinales, histopathologie, immunohistochimie.


Assuntos
Biomarcadores Tumorais , Tumores do Estroma Gastrointestinal , Humanos , Biomarcadores Tumorais/análise , Tumores do Estroma Gastrointestinal/diagnóstico , Tumores do Estroma Gastrointestinal/epidemiologia , Tumores do Estroma Gastrointestinal/metabolismo , Proteínas de Neoplasias/análise , Proteínas de Neoplasias/metabolismo , Estudos Retrospectivos , Nigéria/epidemiologia , Estudos Transversais , Imuno-Histoquímica
3.
Environ Sci Pollut Res Int ; 28(29): 39680-39691, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-33763836

RESUMO

This study was designed at evaluating the acrylamide (ACR) exposure in pregnant Wistar rats as a risk of developing renal disease in their litters. Four groups of pregnant female rats were used. Group 1 control animals were given 2 ml/kg/day of distilled water. Groups 2, 3, and 4 animals were given oral gavage doses of 2, 5, and 10 mg/kg/day of ACR respectively immediately pregnancy was confirmed. Mother rats were sacrificed 10 weeks after delivery and litters were sacrificed at 13 weeks. Proteinuria was observed in ACR-treated mother rats and their litters. Serum electrolytes, urea, and creatinine values observed in the treated group were deranged for both the mothers and litters respectively. Disruption of nephrogenesis was observed in the litters of ACR-treated mother compared to the control. The results of the effect of ACR on lipid profile indicated a significant elevation in the LDL, cholesterol, and triglyceride compared to the control. There was significant reduction in the SOD, catalase, GSH, and significant elevation in the C-reactive protein and malondialdehyde. Conclusively, exposure to acrylamide during pregnancy is a risk factor for the development of renal disease in the mother rats and their litters.


Assuntos
Acrilamida , Estresse Oxidativo , Acrilamida/toxicidade , Animais , Catalase/metabolismo , Feminino , Malondialdeído , Gravidez , Ratos , Ratos Wistar
4.
Sci. med. (Porto Alegre, Online) ; 29(2): ID33630, 2019.
Artigo em Inglês | LILACS | ID: biblio-1022313

RESUMO

AIMS: Evidence shows that diabetic patients may be predisposed to oxidative stress owing to increased glyco-oxidation and lipid peroxidation processes in consequence of chronic hyperglycemia. However, there is dearth of information whether glycemic control positively affects the antioxidant defense system in type 2 diabetes mellitus (T2DM). We investigated the potential association between glycemic control and oxidative stress biomarkers in controlled and uncontrolled diabetic states. METHODS: After obtaining ethical clearance, we included patients receiving metformin with glycated hemoglobin A1c ˂7.0% (glycemic control); newly diagnosed T2DM patients without glycemic control with hemoglobin A1c ˃7.0%; and apparently healthy normoglycemic individuals. The following biomarkers were determined: fasting glycemia level, malondialdehyde, glutathione peroxidase activity, catalase activity, total antioxidant capacity and total cholesterol level. The comparisons between the groups were made by ANOVA. RESULTS: The participants were 260 in number: 80 with controlled diabetes, 80 uncontrolled and 100 controls. All participants were between 40 and 71 years old. Fasting glycemia level and hemoglobin A1c showed significant reductions (p<0.05) in controlled T2DM against the uncontrolled T2DM group, all the same both were significantly higher (p<0.05) against the controls. Likewise, malondialdehyde levels showed significant elevations (p<0.05) correspondingly in both uncontrolled and controlled T2DM against the controls, accompanied with significant reductions (p<0.05) in the antioxidative enzyme activities (glutathione peroxidase activity and catalase activity) and total antioxidant capacity levels against the controls. In addition, total cholesterol was significantly reduced (p<0.05) in controlled T2DM against both uncontrolled T2DM and controls, respectively. There were significant correlations between hemoglobin A1c and oxidative stress biomarkers (p<0.05). CONCLUSION: There was no remarkable difference in oxidative stress states between glycemic controlled and uncontrolled T2DM, despite differences in their fasting glycemia and glycated hemoglobin levels. Our data, therefore, suggest that chronic hyperglycemia and possibly anti-diabetic medication may both equally associate with oxidative stress.


OBJETIVOS: Evidências mostram que pacientes diabéticos podem estar predispostos ao estresse oxidativo devido ao aumento dos processos de oxidação da glicose e peroxidação lipídica em consequência da hiperglicemia crônica. No entanto, há escassez de informações se o controle glicêmico afeta positivamente o sistema de defesa antioxidante no diabetes mellitus tipo 2. Esse estudo investiga a possível associação entre controle glicêmico e biomarcadores de estresse oxidativo em estados glicêmicos controlados e não controlados. MÉTODOS: Após a liberação da comissão de ética, o estudo incluiu pacientes em uso de medicação hipoglicemiante (metformina) com hemoglobina glicosilada A1c ˂7,0% (diabetes controlado), pacientes recém-diagnosticados com diabetes mellitus tipo 2 sem controle glicêmico e com hemoglobina A1c ˃7,0% e indivíduos normoglicêmicos aparentemente saudáveis. Foram determinados os seguintes biomarcadores: glicemia de jejum, malonaldeído, atividade da glutationa peroxidase, atividade de catalase, capacidade antioxidante total e nível de colesterol total. A comparação entre os grupos foi feita pela ANOVA. RESULTADOS: Foram incluídos 260 participantes: 80 com diabetes controlada, 80 não controlada e 100 controles. Todos os participantes tinham entre 40 e 71 anos. A glicemia de jejum e a hemoglobina glicosilada foram significativamente menores (p<0,05) nos diabéticos controlados comparado aos não controlados, e todos os diabéticos apresentaram valores significativamente maiores (p<0,05) que os controles. Da mesma forma, os níveis de malonaldeído foram significativamente maiores (p<0,05) nos diabéticos (controlados e não controlados), assim como valores das atividades antioxidantes (glutationa peroxidase e catalase) e nos níveis de capacidade antioxidante foram significativamente menores (p<0,05) frente aos controles. Além disso, o colesterol total foi significativamente menor (p<0,05) nos diabéticos controlados quando comparados aos não controlados e controles, respectivamente. Houve correlações significativas entre a hemoglobina glicosilada e do estresse oxidativo (p<0,05). CONCLUSÃO: Não houve diferença significativa nos estados de estresse oxidativo entre os diabéticos controlados e não controlados, apesar das diferenças nos níveis de glicose plasmática e hemoglobina glicosilada. Nossos dados, portanto, sugerem que a hiperglicemia crônica e, possivelmente, a medicação antidiabética pode associar-se igualmente ao estresse oxidativo.


Assuntos
Tratamento Farmacológico , Estresse Oxidativo , Diabetes Mellitus Tipo 2 , Hiperglicemia , Medicina , Metformina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...